$VXRT 1/2
Earlier, I was asked to share how I currently value Vaxart (or more precisely… why I don’t see anyone offering >
$1B -
$3B as it stands today in this moment. I explained that I’m not a biotech valuations expert, but that I base it on unbiased AI, precedent, etc.
For full disclosure though, here is the precise output I get from the AI investing engine I built in Argon. I built it to particularly excel at valuations, given how much that affects every other aspect of the investment. To do so, I set it up with API access to Morningstar, GuruFocus, and Unusual Whales, allowing it to see decades of financials and future revenue projections, and using each independent valuation as a challenge to its own conclusions that it must defend. It calibrated to a six-block review that considers multiple valuation methodologies and weights them to reach a conclusion.
Here is the specific output from my Argon engine when prompted to underwrite Vaxart. It’s made for investing more than it’s made for debating on StockTwits, so I have it generate things like a “Good/Great/Legendary” entry zone. I’m leaving it all in there just to give the full picture:
FROM FORTRESS v5.2 ENGINE (ARGON):
$VXRT Institutional 6-Block Valuation and Q3 2026 10-Q Deep Dive (Part 1 of 2): What Is Vaxart Actually Worth Today vs. Post-Phase 2b Data?
Here is a complete, first-principles institutional breakdown of Vaxart (
$VXRT) following the Q3 2026 Form 10-Q filing and Fireside Chat (Nov 5, 2026) -- separating balance sheet reality, clinical Probability of Success (PoS) math, and Sanofi (
$SNY) contract economics from both retail hype and mechanical quant screens.
SECTION 1: EXECUTIVE VERDICT AND ENTRY ZONES
- Classification: Clinical-Stage Binary / Speculative Mucosal Vaccine Platform (OTCQX Listed, Going-Concern Bridge Overhang)
- Current Spot Price (Nov 6, 2026 Close):
$0.3700 per share (243,702,034 shares =
$90.17M Market Cap |
$37.19M Enterprise Value)
- First-Principles 3-Axis Fair Value (Probability-Weighted Today):
$0.77 per share (+108.1% upside to risk-adjusted intrinsic value | Net Cash Floor:
$0.22/sh | Gross Cash:
$0.27/sh)
Speculative Binary Entry Zones (25% / 40% / 55% Haircuts to
$0.77 Fair Value):
- 3-Good Zone (at or below
$0.58): Achieved at spot (
$0.37 trades at a -51.9% discount to probability-weighted fair value, reflecting OTC illiquidity and the Q2 2027 vs. mid-2027 financing bridge).
- 2-Great Zone (at or below
$0.46): Achieved at spot (below the
$0.45/sh price Dynavax paid for its
$5.0M equity stake in Nov 2025).
- 1-Legendary Zone (at or below
$0.35): Deep Net-Cash / 52-Week Low Floor (
$0.34 to
$0.35), where the market prices the entire clinical pipeline at near zero above gross cash (
$0.27/sh) and net working capital (
$0.22/sh).
- Technical Setup: Trading below its 50-DMA (
$0.4586) and 200-DMA (
$0.5804) with a 14-Day RSI of 33.77, resting just +
$0.02 to +
$0.03 above its
$0.34 to
$0.35 52-week volume support shelf.
SECTION 2: VALUATION MULTIPLE STACK AND CASH FLOOR
Because Vaxart's historical revenue is predominantly pass-through BARDA clinical trial reimbursement (
$10.62M in Q3 2026 vs.
$72.40M in Q3 2025 as trial enrollment wound down), traditional P/E multiples are non-meaningful. Institutional biotech desks benchmark
$VXRT on Price-to-Gross-Cash, Price-to-Book, Enterprise Value (EV), and Risk-Adjusted Pipeline rNPV:
1. Price / Gross Cash (
$0.269/sh): Spot (
$0.37) is 1.38x | 5-Yr Phase 2 Peer Median is 1.65x | 3-Good (
$0.58) is 2.16x | 1-Legendary (
$0.35) is 1.30x.
2. Price / Book Value (
$0.272/sh): Spot (
$0.37) is 1.36x | 5-Yr Biotech Peer Median is 1.80x | 3-Good (
$0.58) is 2.13x | 1-Legendary (
$0.35) is 1.29x.
3. Enterprise Value (EV): Spot (
$0.37) is
$37.19M | 5-Yr Phase 2b Vaccine Peer Median is
$115.0M | 3-Good (
$0.58) is
$88.37M | 1-Legendary (
$0.35) is
$32.32M.
4. EV / 9M 2026 Revenue (
$77.0M): Spot (
$0.37) is 0.48x | 5-Yr Peer Median is 2.40x | 3-Good (
$0.58) is 1.15x | 1-Legendary (
$0.35) is 0.42x.
5. Price / Risk-Adjusted Fair Value (
$0.77): Spot (
$0.37) is 0.48x | Peer Benchmark is 1.00x | 3-Good (
$0.58) is 0.75x | 1-Legendary (
$0.35) is 0.45x.
SECTION 3: Q3 2026 10-Q BALANCE SHEET AND BURN AUDIT
Verified directly from Vaxart's Q3 2026 Form 10-Q (ended Sept 30, 2026, filed Nov 5, 2026):
- Cash and Short-Term Investments:
$65,544,000 (
$35.12M cash +
$30.43M short-term investments =
$0.2690 per share). Cumulative BARDA cash received reached
$278.0M as of Sept 30, 2026.
- Government and Collaboration Receivables:
$30,498,000 (
$21.03M accounts receivable +
$9.47M unbilled BARDA receivables) vs.
$62,042,000 in accounts payable (
$29.78M) and accrued current liabilities (
$32.27M).
- Debt and Lease Obligations: Zero traditional bank or bond debt.
$7.22M in operating lease liabilities and
$5.35M in liability related to the sale of future royalties (
$12.57M total debt-like obligations), leaving +
$52.98M (+
$0.2174/sh) in Net Financial Cash and +
$52.50M (+
$0.2154/sh) in Net Working Capital.
- Q3 2026 Burn and SBC: Revenue dropped to
$10.62M (-61.0% QoQ from
$27.2M in Q2;
$7.5M BARDA contract +
$2.9M Dynavax collaboration) while OpEx was
$27.90M (
$22.8M R&D +
$5.1M G&A), producing a -
$17.69M GAAP Net Loss (-
$0.07/sh). Stock-Based Compensation (SBC) was
$1.20M (11.3% of Q3 revenue, down -41% YoY), with +
$2.20M in 9M 2026 operating cash flow driven by BARDA working-capital collections.
- The Critical Q2 2027 vs. Mid-2027 Liquidity Bridge Risk: Management anticipates 5,400-patient BARDA Phase 2b COVID-19 topline data (400 sentinel + ~5,000 main cohort) in mid-year 2027, while stating that current cash (
$65.5M) funds operations into Q2 2027 (triggering an explicit 10-Q Going Concern warning). Unless Vaxart secures a non-dilutive Norovirus partnership or incremental BARDA funding before Spring 2027, it faces a 1-to-2 quarter cash bridge (~
$15M to
$20M) to reach Sanofi's
$50.0M post-Phase 2b COVID opt-in decision -- likely requiring selective draws on the
$25.0M Lincoln Park ELOC (925,000 shares sold for ~
$0.5M through Sept 30) or the
$50.0M ATM (~35M to 45M shares of potential bridge dilution at
$0.37 to
$0.45).
(CONT’D…)
